Goodness Growth Holdings, Inc. a physician-led, science-focused cannabis company and IP developer, today announced that its subsidiary, Vireo Health of Arizona LLC has successfully completed the previously-disclosed divestiture of its dispensary license, all remaining inventory and equipment at its Phoenix dispensary, the Phoenix dispensary property lease and all revenue producing contracts in an all-cash ...

- Goodness Growth Holdings, Inc. ("Goodness Growth") (CSE: GDNS; OTCQX: GDNSF), a physician-led, science-focused cannabis company and IP developer, today announced that its subsidiary, Vireo Health of Arizona LLC ("Company"), has successfully completed the previously-disclosed divestiture of its dispensary license, all remaining inventory and equipment at its Phoenix dispensary, the Phoenix dispensary property lease and all revenue producing contracts in an all-cash transaction valued at $15.0 million .

The transaction also includes related cultivation licenses for both medical and adult-use, only one of which is currently operational at the Company's 18-acre outdoor farm in Amado, AZ , south of Tucson . Goodness Growth also entered into a separate cultivation management services agreement with the acquirer, Copperstate Farms, LLC, which will allow the Company to continue cultivating and selling cannabis products through the medical and adult-use wholesale sales channels in Arizona . The cultivation management services agreement has an initial term of five years and will be subject to renewal for up to 20 years.

"We received significant interest to acquire our Phoenix dispensary and are pleased to have closed a transaction which will allow us to concentrate on growing profitability as a wholesale supplier of biomass in the Arizona market," said Chairman & Chief Executive Officer, Kyle Kingsley , M.D. "Our management team and board of directors felt that this transaction will allow us to focus additional resources on the more attractive opportunities we see in our other markets, especially New York , Maryland , and Minnesota ."

Kingsley concluded, "We originally acquired our Arizona operations in 2019, along with several other cultivation sites in the Southwestern United States , because we were attracted to strategic geographic locations with climates that were suitable for outdoor cultivation. We've since developed and greatly expanded our cultivation facility in Arizona to become one of the lowest-cost outdoor cultivation facilities in the market, and we're pleased to continue operating that facility and servicing the Arizona wholesale market through our management services agreement."

About Goodness Growth Holdings, Inc.

Goodness Growth Holdings, Inc., is a physician-led, science-focused holding company whose mission is to bring the power of plants to the world. The Company's operations consist primarily of its multi-state cannabis company subsidiary, Vireo Health, and its science and intellectual property developer, Resurgent Biosciences. The Company manufactures proprietary, branded cannabis products in environmentally friendly facilities and state-of-the-art cultivation sites and distributes its products through its growing network of Green Goods™ and other retail locations and third-party dispensaries. Its teams of more than 500 employees are focused on the development of differentiated products, driving scientific innovation of plant-based medicines, and developing meaningful intellectual property. Today, the Company is licensed to grow, process, and/or distribute cannabis in eight markets and operates 17 dispensaries across the United States . For more information about Goodness Growth Holdings, please visit www.goodnessgrowth.com .

Forward-Looking Statement Disclosure

This press release contains "forward-looking information" within the meaning of applicable United States and Canadian securities legislation. To the extent any forward-looking information in this press release constitutes "financial outlooks" within the meaning of applicable United States or Canadian securities laws, such information is being provided as preliminary financial results and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information contained in this press release may be identified by the use of words such as "plan," "position," "continue," "will," "expects," "pending," or variations of such words and phrases.  These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management's experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, risks related to current and future economic conditions; risks related to the COVID-19 pandemic; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws in the United States relating to psychedelics  and any changes to such laws; operational, regulatory, and other risks; execution of business strategy; difficulty to forecast; conflicts of interest; liquidity and additional financing; and risk factors set out in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 , which is available on EDGAR with the U.S. Securities and Exchange Commission and filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com .

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results, or otherwise, other than as required by applicable securities laws.

Contact Information


Investor Inquiries:

Media Inquiries:

Sam Gibbons

Albe Zakes

Vice President, Investor Relations

Vice President, Corporate Communications

samgibbons@vireohealth.com

albezakes@vireohealth.com

(612) 314-8995

(267) 221-4800

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/goodness-growth-holdings-closes-previously-announced-divestiture-of-arizona-dispensary-license-301429402.html

SOURCE Goodness Growth Holdings, Inc.

News Provided by PR Newswire via QuoteMedia

BevCanna Announces Strong Third Quarter 2021 Financial Results

BevCanna Announces Strong Third Quarter 2021 Financial Results

Increases revenues by more than 1000 per cent over the comparable quarter of 2020

BevCanna Enterprises Inc. ( CSE:BEV , Q:BVNNF , FSE:7BC ) ("BevCanna" or the "Company"), an emerging leader in innovative health and wellness beverages and products, today reported its unaudited financial results for the quarter ended September 30, 2021.

Keep reading... Show less
Numinus to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th

Numinus to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the H.C. Wainwright 2 nd Annual Psychedelics Conference to be hosted virtually on Monday, December 6, 2021 .

Payton Nyquvest , Founder and CEO of Numinus, will participate in the Psychedelics Assisted Psychotherapy panel at 1:30 p.m. ET . In addition, a corporate presentation by Mr. Nyquvest will be available on-demand. To attend, register here .

Keep reading... Show less

Fab 5 Freddy and Curaleaf Expand B NOBLE Cannabis Brand to New York Medical Market

Now in Ten States, B NOBLE Partnership Advances Social Equity in Cannabis and Provides Opportunity to Those Directly Impacted by the War on Drugs

B NOBLE Inc. and Curaleaf, a leading international provider of consumer products in cannabis, today announced the expansion of its B NOBLE partnership into medical dispensary locations in New York . This expansion is one of the first partnerships of its kind in New York as the New York Cannabis Control Board recently approved whole flower as part of its medical marijuana offerings in late October.

Keep reading... Show less
Avicanna Enters into an Intellectual Property Licensing and Distribution Agreement with Established Pharmaceutical Company in Argentina

Avicanna Enters into an Intellectual Property Licensing and Distribution Agreement with Established Pharmaceutical Company in Argentina

Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce that it has entered into a partnership with an established Argentine pharmaceutical company to register and commercialize Avicanna's proprietary cannabinoid-based pharmaceutical preparations through the licensing of its intellectual property and supply of its active pharmaceutical ingredients ("API").

Through the partnership Avicanna will provide a non-exclusive license of the Company's intellectual property related to its proprietary 10% cannabidiol ("CBD") pharmaceutical drug preparation. Additionally, the partner will source its pharmaceutical-grade CBD exclusively from Avicanna to manufacture the product for the registration and marketing authorization with the Argentine regulatory agency ANMAT.

Keep reading... Show less
Tinley's Announces Q3 2021 Results and Provides Corporate Updates

Tinley's Announces Q3 2021 Results and Provides Corporate Updates

The Tinley Beverage Company Inc. (CSE:TNY; OTC:TNYBF) ("Tinley's" or the "Company") is pleased to provide corporate updates to coincide with the release today of the Company's condensed interim consolidated financial statements and management's discussion and analysis thereon for the three and nine months ended September 30, 2021, which are accessible under the Company's profile on SEDAR at www.sedar.com .

Third Quarter 2021 Financial Highlights

Keep reading... Show less

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Cronos Group Inc. with Losses of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofCronos Group Inc. ("Cronos" or "the Company") (NASDAQ:CRON) for violations of the securities laws

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Cronos filed a Form 8-K with the SEC on November 9, 2021, disclosing that the Company would "be required to restate its previously issued unaudited interim financial statements for the three and six months ended June 30, 2021" and that "the Company's financial statements for this period should therefore no longer be relied upon." Based on this news, shares of Cronos fell by nearly 16%.

Keep reading... Show less

Top News

Related News